semaglutide news october 20 2025 Expert Review,20

October 20, 2025, emerges as a significant date in the ongoing narrative of semaglutide, a groundbreaking medication primarily known for its role in weight management and diabetes treatment. This period is characterized by a flurry of news and developments, including key presentations at ObesityWeek® 2025, updates on FDA approvals, and insights into the evolving landscape of GLP-1 receptor agonists.

Novo Nordisk, the pharmaceutical giant behind semaglutide and its branded forms like Ozempic and Wegovy®, is at the forefront of these advancements. The company is set to present new data on oral semaglutide 25 mg (marketed as Wegovy® in a pill*) at ObesityWeek® 2025. This presentation is expected to shed further light on the efficacy and potential of this oral formulation, which has been a major focus for Novo Nordisk in 2025. Indeed, Novo Nordisk has been "all in on weight loss" throughout 2025, with sales of Wegovy® showing substantial growth.

The news surrounding semaglutide in October 2025 also highlights significant regulatory milestones. The US FDA has approved a once daily pill version of Wegovy®, a development that marks a new era for oral administration of this class of drugs. This approval is a culmination of extensive research and trials, aiming to provide a more convenient option for patients. Furthermore, the FDA Approves Novo Nordisk's Oral Rybelsus for Cardiovascular Risk Reduction in adults with type 2 diabetes who are at high risk. This dual indication for semaglutide underscores its expanding therapeutic potential beyond glucose control and weight loss.

In the realm of weight loss, semaglutide continues to be a leading contender. A new study presented on October 20, 2025, indicates that the Wegovy® pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects, according to an indirect comparison. This positions semaglutide favorably within the competitive market of new weight loss drugs in 2025. Another key finding from the STEP UP trials revealed that a higher semaglutide dose of 7.2 mg led to greater weight loss compared to the currently approved 2.4 mg dose, suggesting potential for dose optimization in the future.

However, the news is not without its complexities. Real-world studies are providing crucial insights into patient adherence. Data released in September 2025 indicated that more than half of adults in Denmark without diabetes have discontinued semaglutide for weight loss within a year, with young adults being the most likely to stop. Similarly, another study found that half of people who start taking Ozempic for weight loss discontinue the drug within a year. These findings highlight the importance of understanding patient experiences and potential challenges associated with long-term semaglutide use.

The semaglutide market is also experiencing shifts. The semaglutide shortage is ending, with the FDA announcing in February 2025 that the shortage of injectable semaglutide had largely been resolved. This development is crucial for ensuring continued patient access to this vital medication. Concurrently, a "massive shake-up is underway in India's obesity and diabetes drug market as the patent for Semaglutide" is nearing its expiration, potentially leading to increased competition and expanded access.

Beyond weight loss and diabetes, semaglutide is also being investigated for other conditions. While Novo Nordisk has reported setbacks with two phase 3 trials of semaglutide as a treatment for Alzheimer's disease, research continues in other areas. For instance, an FDA approval in October 2025 was granted for a 2.4-mg injection of semaglutide for adults with noncirrhotic metabolic dysfunction–associated steatohepatitis (MASH).

Looking ahead, the market for GLP-1 drugs is projected for substantial growth, with leading GLP-1s expected to reach $50 billion in 2025 sales. Novo's Ozempic is anticipated to retain its top spot. The potential of GLP-1 drugs to revolutionize medicine, beyond their established roles, exploded in 2025, with innovations like oral semaglutide leading the charge.

In summary, October 20, 2025, represents a dynamic period for semaglutide. The month is marked by advancements in oral formulations, expanded FDA approvals for both cardiovascular risk reduction and MASH, and ongoing discussions about real-world effectiveness and patient adherence. Developments such as ASC30, Mazdutide Beats Semaglutide in certain contexts, alongside the continued exploration of **semagl